News & Events
Company news, scientific milestones, and upcoming events.
A new kidney–brain axis study co-authored by Padakonn Pharma researcher Alexei Y. Bagrov was published by Bentham Science in Current Neuropharmacology.
Padakonn Pharma’s anti-MBG monoclonal antibodies have entered TRL5 validation using blood samples from patients with chronic kidney disease.
Padakonn Pharma has been selected to join Health Founders Estonia for the second year in a row and will take part in Batch II of the DEVELOP programme.
Padakonn Pharma has been selected to join the UK Government’s Global Entrepreneur Programme, supporting the company’s growth and partnerships in the UK life sciences ecosystem.
Grant support for Padakonn Pharma’s €1.5M TRL5 research project in chronic kidney disease.